Skip to main content
Premium Trial:

Request an Annual Quote

Theralink Technologies: Faith Zaslavsky, Mick Ruxin

Theralink Technologies has appointed Faith Zaslavsky as CEO. She will take the helm from Mick Ruxin, who will transition to the role of chief medical officer. Zaslavsky has served as the company's president and chief operating officer since December 2022. Prior to that, she spent more than 20 years at Myriad Genetics, most recently as president of oncology, where she was instrumental in the commercialization of tests to detect mutations in the BRCA1 and BRCA2 genes.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.